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Background: Dornase alfa (DNase) is one of the commonest cystic ﬁbrosis (CF) treatments and is often used for many years. However, studies
have not evaluated the effectiveness of its long-term use. We aimed to use UK CF Registry data to investigate the effects of one-, two-, three-, four-
and ﬁve-years of DNase use on lung function to see if the beneﬁts of short-term treatment use are sustained long term.
Methods: We analysed data from 4,198 people in the UK CF Registry from 2007 to 2015 using g-estimation. By controlling for time-dependent
confounding we estimated the effects of long-term DNase use on percent predicted FEV1 (ppFEV1) and investigated whether the effect differed by
ppFEV1 at treatment initiation or by age.
Results: Considering the population as a whole, there was no signiﬁcant effect of one-year's use of DNase; change in ppFEV1 over one year was
−0.1% in the treated compared to the untreated (p = 0.51) and this did not change with long-term use. However, treatment was estimated to be more
beneﬁcial in people with lower lung function (p b 0.001); those with ppFEV1 b 70% at treatment initiation, showed an increase in lung function
over one year that was sustained out to ﬁve years. The estimated effect of DNase did not depend on age (p = 0.35).
Conclusions: DNase improved lung function in individuals with reduced lung function, bringing a step-change in lung function, but no change in
the slope of decline. There was no evidence for a beneﬁt in lung function in those initiating treatment with ppFEV1 N 70%.
© 2018 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: DNase; Long-term treatment effect; Patient registry; UK Cystic Fibrosis Registry1. Background
First licensed for use in the EU and the US in 1994, dornase
alfa (DNase) is now one of the commonest cystic fibrosis (CF)
treatments, used by almost 60% of people with CF in the UK in
2016 [1,2]. DNase is a mucolytic treatment administered via a
nebulizer, decreasing the viscosity of sputum in the airways,
aiming to aid in airway clearance, to improve lung function and
decrease pulmonary exacerbations [3].⁎ Corresponding author.
E-mail address: simon.newsome@lshtm.ac.uk (S.J. Newsome).
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org/10.1016/j.jcf.2018.08.004mdornIn a phase III clinical trial, using DNase once or twice daily
over twenty-four weeks was shown to improve percent-
predicted FEV1 (ppFEV1) [4]. Subsequently, a number of
studies have examined the effect of longer-term use of DNase.
For example, after 96 weeks of follow-up, treatment was shown
to significantly improve ppFEV1 in children aged 6 to 10 [5,6].
Most studies have focused on the absolute effect of DNase
on lung function over a specified time period, i.e. on a step-
change effect. Its impact on the rate of lung function decline is
also important and this has been investigated in two studies.
These studies showed that during DNase use the rate of lung
function decline was less than the rate of decline in the samease alfa use on lung function using registry data, J Cyst Fibros (2018), https://doi.
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Fig. 1. Flowchart of people included in analysis.
2 S.J. Newsome et al. / Journal of Cystic Fibrosis xx (2018) xxx–xxxpatients prior to starting treatment and also less than the rate of
decline in a comparator group of patients who never received
treatment [7,8]. Only one study has attempted to evaluate the
impact of using DNase for more than two years. This was a
matched study with 76 patients where it was found that those
receiving treatment over four years had a more gradual slope of
decline in ppFEV1 [9].
Until recently in the UK regional guidelines for CF use of
DNase varied, but DNase tended to be recommended when a
person's ppFEV1 fell below 80%. However, in 2014 a national
policy was approved allowing the use of DNase in anyone over
six years of age. Thus, more recently, some centres have begun
to routinely initiate DNase when a patient reaches six years of
age. These differences in treatment practices provide an
opportunity to use the UK CF Registry data to investigate the
long-term effects of DNase in a diverse population.
There are, however, some challenges that must be addressed
when attempting to use observational data for this purpose. The
main issue when estimating treatment effects is confounding by
indication, whereby more healthy individuals are less likely to
receive treatment. A simple comparison of treated and
untreated would therefore typically suggest that even an
effective treatment is associated with worse outcomes. A
further complexity of Registry data is that as it is longitudinal,
not only do confounding variables affect both the outcome of
interest and the probability of receiving treatment, but they are
also themselves affected by whether the patient was receiving
treatment or not in previous years. This issue is known as time-
dependent confounding and traditional statistical methods will
generally lead to biased results. There are several methods
available that can deal with time-dependent confounding
[10,11], including inverse probability weighted estimation of
marginal structural models, g-computation formula and g-
estimation. A recent investigation of the application of these
methods using registry data showed that for a continuous
outcome, such as lung function, g-estimation appeared to be the
most reliable and flexible, in particular by accommodating
estimation of treatment effect modification by a time-varying
covariate [12].
In this paper, we aimed to use the UK CF Registry to
investigate the effects of one-, two-, three-, four- and five-years
of DNase use on lung function. Furthermore, we aimed to
investigate whether there is evidence that treatment is more
effective in younger people, as has previously been reported
[7]. We also hypothesised that the effect of DNase may differ
depending on lung function, and as such we examined whether
there is evidence that the treatment effect is modified by
previous measures of lung function.
2. Methods
2.1. UK cystic ﬁbrosis registry
The UK Cystic Fibrosis Registry is a national database
managed by the Cystic Fibrosis Trust. Each year people with
CF attend an annual assessment at which data are collected on
their current health as well as on the treatments they havePlease cite this article as: Newsome SJ, et al, Investigating the effects of long-term dorn
org/10.1016/j.jcf.2018.08.004received in the past year. More details about the registry can be
found in the data resource profile [13].
People were eligible for inclusion in the study if they had at
least two consecutive years of data in the Registry between
2007 and 2015, had not received DNase prior to 2007, had at
least one year of treatment-free data, were at least six years old,
had lung function data for at least two consecutive years and
had not received a lung transplant. The first visit for everyone
was therefore at a time when they were not and had never
before received DNase treatment. Follow-up data were
collected up to 2015, or were censored at death, transplant or
loss to follow-up. If people who started receiving DNase
stopped during their follow-up, they were censored at the time
they stopped treatment. Fig. 1 shows a flow chart of the number
of people included and excluded from the study population.
For this study, the primary outcome was change in lung
function expressed as absolute change over time in ppFEV1
calculated using the Global Lung Initiative (GLI) calculations
[14]. Secondary analyses with ppFVC and ppFEF25–75 as
outcomes were also conducted. All outcomes are observed
annually.
As well as previous measures of the outcome and DNase, we
also adjusted for the following time-varying variables: annual
number of hospital and home IV days, CF centre, other muco-ase alfa use on lung function using registry data, J Cyst Fibros (2018), https://doi.
3S.J. Newsome et al. / Journal of Cystic Fibrosis xx (2018) xxx–xxxactive treatments, smoking status, CF related diabetes (CFRD),
body mass index (BMI), allergic bronchopulmonary aspergil-
losis (ABPA) and infections (P. aeruginosa, S. aureus and B.
cepacia complex); and the following non-time-varying vari-
ables: age, gender, ethnicity and genotype class (as defined by
McKone et al) [15]. These were selected from the data collected
in the Registry as variables that could affect both lung function
and the decision to initiate DNase.
2.2. Statistical methods
In a preliminary exploration of the data, baseline covariates,
i.e. those measured at the first visit, were summarised in all
patients and separately in the following four subgroups: those
who never received DNase, those who received DNase for at
least one year, those who received DNase for at least five years,
and those who stopped DNase during follow-up. Time-varying
covariates were summarised across visits in the following five
groups: at a patient's first visit, at subsequent visits among
people not receiving DNase, at the first visit when people
received DNase, at subsequent visits among people receiving
DNase, and at the visit when people stopped receiving DNase.
We also performed a univariable linear regression to estimate
the crude difference in lung function between those receiving
and not receiving treatment.
Data were then analysed using g-estimation to investigate
the causal effect of up to five years of DNase use on lung
function [16]. A recent paper by Vansteelandt and Sjolander
has shown how to implement this method using standard
statistical software [17]. Full details of this method can be
found in the supplementary material to this paper. Briefly, the
method works iteratively by first estimating a one-year
treatment effect adjusting for the confounders of this effect,
then estimating any additional two-year treatment effect
adjusting for the relevant confounders of this effect and so on
until the maximum follow-up time of interest (five years in our
case). Thus, we obtain five different treatment effect estimates;
these are the estimated differences in lung function between
those using DNase for k years (k = 1, …, 5) and those never
receiving treatment, with the time-dependent confounding
having been adjusted for at each stage.
Evidence that the treatment effect is modified by age or by
previous lung function was investigated by including an
interaction term between the relevant variable and DNase use
at each visit.
For g-estimation, standard errors used to calculate p-values
and 95% confidence intervals were estimated using the non-
parametric bootstrap approach [18]. All analyses were per-
formed using Stata (version 15.0, Stata Corp, College Station,
Texas, USA).
3. Results
Overall, 4,198 people were included in the analysis, with a
combined total of 20,923 annual assessments. The median
number of follow-up visits per person was 5 (IQR 3–7). During
follow-up, 2,384 (56.8%) people received DNase for at leastPlease cite this article as: Newsome SJ, et al, Investigating the effects of long-term dorn
org/10.1016/j.jcf.2018.08.004one year, and most people who started using DNase continued
to receive it indefinitely, with only 441 (18.5%) people
stopping during follow-up. In total, 787 people had five or
more consecutive years of DNase use.
Table 1 summarises the variables that were considered as
confounders for the main analysis. When looking at this
summary of the data, we found that those taking DNase tend to
have worse symptoms. This is expected, because those needing
treatment are expected to be in worse health. This finding is
part of the phenomenon of confounding by indication.
Particularly, the mean ppFEV1 measured prior to visits when
people were not receiving DNase was 80% compared to 72%
prior to the visit when people started to receive DNase.
Furthermore, the group who ever received DNase had a higher
proportion of people with a high genotype class (76% vs 57%),
a higher proportion with CFRD (23% vs 18%) and had more
annual IV days (mean annual hospital IV days 10 vs 5, and
mean annual home IV days 9 vs 5). Table 1 also summarises
the group of people who stopped taking DNase during follow-
up, but there were no noticeable differences between this group
of people and those who continued to take DNase throughout
follow-up.
Results from the univariable analysis (row 1 of Table 2)
show that people receiving DNase had lower lung function
compared to those not receiving treatment throughout follow-
up. For example, at one year those receiving DNase had a lung
function on average 7.1% lower than those not receiving
treatment (95% CI -8.1% to −6.1%, p b 0.0001). Furthermore,
the average annual decline in ppFEV1 was 1.0% (95% CI 0.9%
to 1.2%) in those not taking DNase compared to 1.3% (95% CI
1.1% to 1.5%) in those receiving DNase.
The results from the causal analysis using g-estimation are
shown in Table 2 and Fig. 2. On a population level, we found
no significant effect of DNase on ppFEV1, with those on
treatment estimated to have an absolute change in lung function
of −0.1% over one year compared to someone not receiving
treatment (95% CI -0.6% to 0.4%, p = 0.65). However, by year
two this effect became more pronounced with an estimated
difference of −0.7% (95%CI–1.4% to 0.05%, p = 0.069), and
this trend continued out to year five, when it was estimated that
on average receiving treatment for 5 years, compared to never
receiving DNase, would result in an absolute change in lung
function of −3.3% (95% CI -4.9% to −1.7%, p b 0.0001).
We found strong evidence that the effect of treatment differs
depending on previous lung function (p b 0.001), with
beneficial effects seen in those with low lung function. This is
illustrated in Fig. 2, where beneficial effects are shown over the
5-year duration for people with baseline ppFEV1 b70%,
whereas for those with baseline ppFEV1 N70% the rate of
decline was steeper in those receiving treatment. For example,
for an individual with baseline ppFEV1 of 40%, initiating
DNase was estimated to result in a lung function 1.6% higher
after one year (95% CI 0.6% to 2.7%, p = 0.002) compared to
not initiating DNase. Conversely, for an individual with a
baseline ppFEV1 of 80%, initiating DNase was estimated to
result in a lung function 0.4% lower after one year (95% CI
-0.1% to 0.9%, p = 0.13) compared to not initiating DNase.ase alfa use on lung function using registry data, J Cyst Fibros (2018), https://doi.
Table 1
Descriptive Statistics of Key Variables. Data presented as mean (SD) for continuous variables and n (%) for binary and categorical variables.
Demographics (4,198 people)
All (n = 4,198) Never used DNase
(n = 1,814)
DNase use ≥ 1
year (n = 2,384)
DNase use ≥ 5 years
(n = 787)
Stopped DNase during
follow-up (n = 441)
Baseline age (Years) 19.8 (12.7) 21.4 (13.5) 18.7 (11.9) 19.1 (11.2) 21.0 (11.1)
Female 1923 (45.8) 806 (44.4) 1117 (46.9) 361 (45.9) 210 (47.6)
Caucasian 4061 (96.7) 1761 (97.1) 2300 (96.5) 758 (96.3) 432 (98.0)
Genotype class a
High 2828 (67.4) 1031 (56.8) 1797 (76.1) 629 (79.9) 333 (75.5)
Low 563 (13.4) 353 (19.5) 210 (8.8) 51 (6.5) 35 (7.9)
None assigned 153 (3.6) 353 (19.5) 301 (12.6) 80 (10.2) 56 (12.7)
Missing 654 (15.6) 77 (4.2) 76 (3.2) 27 (3.4) 17 (3.9)
Longitudinal Data (20,923 observations)
First Visit [nobody
using DNase] (n = 4,198)
Visits where not
using DNase (n = 12,194)
First year using DNase
(n = 2,384)
Subsequent years
using DNase (n = 5,904)
Year after stopping
DNase (n = 441)
Previous ppFEV1
d 80.1 (20.9) 72.0 (21.8) 67.1 (21.9) 66.8 (22.6)
Annual change in ppFEV1
d −1.0 (9.9) −0.4 (12.5) −1.6 (9.5) −1.7 (9.5)
Previous ppFVCb d 90.1 (17.1) 84.5 (18.4) 81.4 (18.6) 81.3 (19.0)
Annual change in ppFVCb d −0.7 (10.1) −0.3 (12.1) −1.2 (10.1) −1.3 (9.8)
Previous ppFEF25–75
c d 71.4 (31.2) 63.9 (30.1) 58.1 (27.4) 59.3 (32.8)
Annual change in ppFEF25–75
c d −1.3 (21.7) 0.1 (26.7) −1.0 (19.4) −5.4 (22.9)
BMI (z-score) 0.13 (1.14) 0.29 (1.18) 0.00 (1.13) −0.02 (1.14) −0.02 (1.20)
Smoker
No 3058 (72.8) 10,567 (86.7) 2138 (89.7) 5310 (89.9) 387 (87.8)
Occasionally 33 (0.8) 126 (1.0) 19 (0.8) 45 (0.8) 6 (1.4)
b1 packet per day 49 (1.2) 256 (2.1) 24 (1.0) 47 (0.8) 12 (2.7)
≥1 packet per day 20 (0.5) 69 (0.6) 6 (0.3) 14 (0.2) 3 (0.7)
Missing 1038 (24.7) 1176 (9.6) 197 (8.3) 488 (8.3) 33 (7.5)
Infections
P. aeruginosa 2453 (58.4) 6460 (53.0) 947 (39.7) 2136 (36.2) 164 (37.2)
S. aureus 2643 (63.0) 7170 (58.8) 1324 (55.6) 3504 (59.3) 250 (56.7)
B. cepacia complex 80 (1.9) 334 (2.7) 86 (3.6) 271 (4.6) 17 (3.9)
ABPA 215 (5.1) 857 (7.0) 274 (11.5) 909 (15.4) 53 (12.0)
CFRD
No 2226 (53.0) 7456 (61.1) 1360 (57.0) 3083 (52.2) 224 (50.8)
Yes 504 (12.0) 2150 (17.6) 550 (23.1) 1812 (30.7) 125 (28.3)
Missing 1468 (35.0) 2588 (21.2) 474 (19.9) 1009 (17.1) 92 (20.9)
Annual hospital IV days 4.1 (11.0) 4.5 (12.2) 10.4 (18.9) 12.4 (23.7) 11.6 (22.8)
Annual home IV days 4.1 (12.5) 4.7 (13.7) 9.0 (18.9) 10.5 (19.8) 10.7 (23.8)
Other muco-active treatments 200 (4.8) 1578 (12.9) 502 (21.1) 1940 (32.9) 136 (30.8)
Acetylcysteine 15 (0.4) 133 (1.1) 41 (1.7) 93 (1.6) 4 (0.9)
Hypertonic saline 184 (4.4) 1440 (11.8) 469 (19.7) 1831 (31.0) 130 (29.5)
Mannitol 2 (0.05) 39 (0.3) 13 (0.5) 124 (2.1) 7 (1.6)
a Genotype class as defined by McKone et al. [15].
b FVC data based on 20,714 observations,
c FEF25–75 data based on 3320 observations,
d First visit, so no previous measures available.
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Table 2
Estimated Effect of DNase Use on percent predicted FEV1 compared to never taking DNase.
Years of DNase use
1 2 3 4 5
Est 95% CI Est 95% CI Est 95% CI Est 95% CI Est 95% CI
Results from univariable analysis
Estimated population average effect
−7.1 −8.1, −6.1 −8.6 −9.7, −7.4 −10.6 −11.9, −9.3 −12.6 −14.0, −11.1 −14.2 −15.9, −12.6
Results from G-Estimation Analysis
Estimated population average effect
−0.1 −0.6, 0.4 −0.7 −1.4, 0.05 −1.4 −2.3, −0.6 −2.5 −3.8, −1.3 −3.3 −4.9, −1.7
Estimated effect by baseline ppFEV1
20% 2.6 1.1, 4.2 2.0 −0.1, 4.2 0.9 −1.7, 3.6 3.0 −0.5, 6.5 4.1 −0.5, 8.7
40% 1.6 0.6, 2.7 1.0 −0.4, 2.5 0.1 −1.8, 1.9 0.9 −1.5, 3.3 1.2 −1.9, 4.4
60% 0.6 −0.01, 1.2 0.1 −0.9, 1.0 −0.8 −1.9, 0.4 −1.2 −2.7, 0.3 −1.6 −3.5, 0.3
80% −0.4 −0.9, 0.1 −0.9 −1.6, −0.2 −1.6 −2.6, −0.7 −3.3 −4.5, −2.0 −4.5 −6.2, −2.8
100% −1.4 −2.2, −0.6 −1.9 −3.0, −0.8 −2.5 −3.9, −1.0 −5.4 −7.4, −3.4 −7.3 −10.0, −4.6
Estimated change in effect per 10% change in baseline ppFEV1
−0.5 −0.8, −0.2 −0.5 −0.9, −0.1 −0.4 −0.9, 0.003 −1.0 −1.7, −0.4 −1.4 −2.2, −0.6
5S.J. Newsome et al. / Journal of Cystic Fibrosis xx (2018) xxx–xxxThe results from the g-estimation analysis provide informa-
tion on whether any impact of DNase on lung function is in the
form of a step change or whether the treatment modifies the
slope of decline. In the groups for which we found a beneficial
effect of treatment, the results were consistent with DNase
resulting in a one-off step change in lung function, rather than a
change in overall trajectory. Full results can be seen in Table 2,
but taking individuals who start treatment with a baseline
ppFEV1 of 40% as an example, the estimated difference in
absolute change in lung function at 5 years was of 1.2% (95%
CI -1.9% to 4.4%, p = 0.44), very similar to the 1.6% benefit
seen at one year.
We found no evidence that the effect of treatment on lung
function differed depending on age at treatment initiation, p =
0.61. (Results of this analysis can be found in the supplemen-
tary material).
We also performed analyses to investigate the effect of
DNase on FVC and FEF25–75 and these results can be seen in
supplementary material. The results from these analyses were
broadly similar to the findings from the FEV1 analysis.4. Discussion
We used UK CF Registry data to estimate long-term effects
of DNase use, controlling for confounding by indication by
using state-of-the-art statistical methodology not previously
applied to CF registry data. In our study, for individuals with a
reduced lung function and not using DNase, we have shown
that initiating DNase treatment and using it for one year brings
a benefit such that ppFEV1 is higher after one year than it
would have been had those individuals not initiated DNase
treatment. This beneficial effect appeared to remain with
continued use of DNase out to five years, but with no overall
modification of the lung function trajectory, as the estimated
effect remained stable between years one and five.Please cite this article as: Newsome SJ, et al, Investigating the effects of long-term dorn
org/10.1016/j.jcf.2018.08.004One reason why it is important to estimate long-term effects
of treatment is to see if a treatment modifies overall lung-
function trajectory or just provides a one-off increase [19,20].
Fig. 3 shows two hypothetical lung-function trajectories for an
individual treated with DNase compared to the lung-function
trajectory of someone not receiving treatment. These trajecto-
ries show how treatment could either be disease modifying,
where the lung function of those receiving treatment continues
to grow wider apart from the lung function of those not
receiving treatment, or alternatively how the overall lung-
function trajectory could remain unchanged after an initial
increase.
Crude comparisons between those who received and did not
receive DNase clearly indicate that there is confounding by
indication, such that individuals taking DNase tend to have
worse health status than those not taking DNase. If this is not
appropriately handled in the analysis, any estimates of the
treatment effect would not have a causal interpretation. In this
study, we made use of appropriate statistical methods to address
the confounding by indication, accounting for the longitudinal
setting, thereby showing how registries can be used to evaluate
the long-term effects of treatment. Randomised controlled trials
(RCT) are the gold standard for establishing treatment efficacy,
but as previously discussed, it is preferable for a CF treatment
to alter lung function trajectory rather than to provide a one-off
improvement, and assessing change in trajectory requires
longer follow-up than would typically be feasible in trials
[21]. The analyses used in this paper take advantage of clear
heterogeneity in treatment practices as the proportion of
patients receiving DNase at individual CF centres ranges from
b20% to N80% [2]. As the groups who receive and do not
receive DNase include individuals with wide-ranging clinical
characteristics, the statistical methods used in this paper can
correct for confounding by indication as long as data on all
confounders have been collected. We were able to adjust for a
large number of variables using the data available in the UK CFase alfa use on lung function using registry data, J Cyst Fibros (2018), https://doi.
Fig. 3. Examples of possible lung function trajectories depending on treatment
effect through time.
Fig. 2. Estimated mean difference in the change in ppFEV1 between dornase alfa users compared to non-users (dashed grey line), by years of treatment. The top-left
figure shows the estimated overall average population effect, with the remaining figures highlighting the differential effects based on ppFEV1 at treatment initiation.
The horizontal dashed grey line is the line indicating no treatment effect.
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org/10.1016/j.jcf.2018.08.004Registry, but it is not possible to verify whether confounding by
indication has ever been completely dealt with and the causal
interpretation of our results therefore depends on the assump-
tion of no unmeasured confounding [22].
A previous registry study by Hodson et al. of the
European Epidemiologic Registry of Cystic Fibrosis esti-
mated a one-year treatment effect of DNase on ppFEV1 of
3.6% (95% CI 1.8% to 5.3%) and a two-year treatment
effect of 2.5% (0.7% to 4.4%) [7]. These are larger
population-average treatment effect estimates than obtained
in our study, but the population for those studies had lower
average baseline ppFEV1, who were the patients we found
benefitted most from treatment.
Only two previous studies have investigated the effects of
DNase in people with ppFEV1 N 80% and only one of thesease alfa use on lung function using registry data, J Cyst Fibros (2018), https://doi.
7S.J. Newsome et al. / Journal of Cystic Fibrosis xx (2018) xxx–xxxincluded lung function as an outcome [23,24]. That study only
administered DNase for four weeks and found no effect of
treatment on ppFEV1: treatment effect 0.1% increase in
ppFEV1 [24]. In our study, for individuals with higher lung
function, those on DNase treatment had steeper trajectories of
lung function decline than comparable individuals not receiving
treatment. This may suggest that it would be more beneficial, in
terms of lung function outcomes, to wait until lung function
starts to decline before initiating DNase. However, as with all
observational studies, it is possible that unobserved con-
founders affect these results. With the rich Registry data, we
believe we have accounted for the covariates that could affect
both lung function and the probability of receiving DNase
treatment to account for confounding by indication, but it is
possible that there are some unmeasured health-related
variables that affected the decisions to initiate treatment in
these individuals. For example, although an individual may
have had a high lung function measurement at the previous
annual assessment, they may have been beginning to show
signs of lung function deterioration that was not picked up by
having only one lung function measure per year.
Upon initiation of DNase, most people continue to receive
the treatment indefinitely, with only very small numbers of
people stopping treatment. Due to this, with the sample size
available, it was not possible to estimate the effect of stopping
treatment. However, as we observed that treatment only
appeared to be beneficial in individuals with reduced lung
function, future studies could investigate whether treatment
needs to be continued in people who recover to higher levels of
lung function.
A major strength of this study is the use of the UK CF
Registry data, which are collected at regular intervals according
to a standardised protocol. The data include a large number of
variables that we could account for as potential confounders.
One of the main limitations of this study is that there are no data
available on levels of adherence to treatment. It is known to be
particularly hard to measure adherence levels, but previous
studies have estimated that average adherence levels to
nebulised therapies, such as DNase, may range between 60%
and 70% [25,26]. Specifically, for a longitudinal study, we may
expect adherence levels to be higher at treatment initiation and
decrease through time, which may partly explain why the
observed effects are not as pronounced as in RCT, where
adherence would typically be higher [27].
The UK CF Registry contains data on over 99% of people
with CF in the UK, but a large number of these people were
excluded from this analysis. The majority of these exclusions
were due to people who were already receiving DNase prior to
2007 or people aged under six, and this is not considered to be a
source of bias. Our results are applicable to people aged over
six and estimate the effects of the first five years of DNase use.
The method of g-estimation relies on having equally spaced
visits, and therefore a number of people were censored due to
missing lung function measurements during follow-up. We
used so-called ‘censoring weights’ within g-estimation, which
reweights individuals who remain in the study to account for
those lost to follow-up.Please cite this article as: Newsome SJ, et al, Investigating the effects of long-term dorn
org/10.1016/j.jcf.2018.08.004The analyses presented in this paper use the FEV1 measure
obtained on the date of a patient's annual review. An alternative
approach would be to use the best FEV1 measure obtained since
the last annual review. However, best FEV1 has only been
collected in the UK CF Registry since 2012 and the aim of this
paper, to estimate the effects of long-term DNase use, would
not be possible with the number of best FEV1 observations
available. The unknown timing of the best FEV1 measure
relative to the other measures would also present additional
challenges for the analysis. According the Registry protocol,
annual reviews take place at a time when the patient is stable,
and ongoing validation procedures indicate good adherence to
this protocol [28]. Furthermore, there is no evidence to suggest
that those receiving DNase are more likely to have their annual
review during an unstable period compared to those not
receiving DNase, meaning that using the FEV1 measure
obtained during the annual assessment should not result in
any bias.
It is also acknowledged that spirometry measures, such as
FEV1, may not be sufficiently sensitive to detect the early
stages of lung function decline, and it has been suggested that
other measures such as lung clearance index (LCI) may give a
better indication of early lung function deterioration [29,30].
Unfortunately, LCI is not collected in the UK CF Registry, so it
was not possible to investigate this. However, FEF25–75 is
collected in the registry, albeit less reliably than FEV1 (3320
FEF25–75 measurements compared to 20,923 FEV1 measure-
ments in this analysis), and the results showed similar findings
to the findings with FEV1, but with much larger confidence
intervals, reflecting the lack of measurements and increased
variability of this measure (see Supplement).
In conclusion, we have shown a beneficial long-term effect
of DNase in people with reduced lung function, but with no
overall change in lung-function trajectory. There is a differen-
tial effect of treatment based on lung function at treatment
initiation with no improvements in lung function seen in
individuals initiating treatment with ppFEV1 higher than 70%.
Finally, this study highlights the potential of registries in
investigating the effects of long-term treatment use and that
issues of confounding-by-indication can be addressed with
appropriate statistical methods.Funding & competing interests
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